The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.
Autoantibody Specificities in Myasthenia Gravis; Implications for Improved Diagnostics and Therapeutics
Open accessAbstract
Myasthenia gravis (MG) is an autoimmune disease characterized by muscle weakness and fatiguability of skeletal muscles. It is an antibody-mediated disease, caused by autoantibodies targeting neuromuscular junction proteins. In the majority of patients (~85%) antibodies against the muscle acetylcholine receptor (AChR) are detected, while in 6% antibodies against the muscle-specific kinase (MuSK) are detected. In ~10% of MG patients no autoantibodies can be found with the classical diagnostics for AChR and MuSK antibodies (seronegative MG, SN-MG), making the improvement of methods for the detection of known autoantibodies or the discovery of novel antigenic targets imperative. Over the past years, using cell-based assays or improved highly sensitive immunoprecipitation assays, it has been possible to detect autoantibodies in previously SN-MG patients, including the identification of the low-density lipoprotein receptor-related protein 4 (LRP4) as a third MG autoantigen, as well as AChR and MuSK antibodies undetectable by conventional methods. Furthermore, antibodies against other extracellular or intracellular targets, such as titin, the ryanodine receptor, agrin, collagen Q, Kv1.4 potassium channels and cortactin have been found in some MG patients, which can be useful biomarkers. In addition to the improvement of diagnosis, the identification of the patients’ autoantibody specificity is important for their stratification into respective subgroups, which can differ in terms of clinical manifestations, prognosis and most importantly their response to therapies. The knowledge of the autoantibody profile of MG patients would allow for a therapeutic strategy tailored to their MG subgroup. This is becoming especially relevant as there is increasing progress towards the development of antigen-specific therapies, targeting only the specific autoantibodies or immune cells involved in the autoimmune response, such as antigen-specific immunoadsorption, which have shown promising results. We will herein review the advances made by us and others towards development of more sensitive detection methods and the identification of new antibody targets in MG, and discuss their significance in MG diagnosis and therapy. Overall, the development of novel autoantibody assays is aiding in the more accurate diagnosis and classification of MG patients, supporting the development of advanced therapeutics and ultimately the improvement of disease management and patient quality of life.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oosterhuis, H. (1997) · Cited by 2,397
Hoch, W., McConville, J., Helms, S., Newsom-Davis, J., Melms, A., & Vincent, A. (2001) · Nature Medicine · doi:10.1038/85520 · Cited by 1,183
Induction, assembly, maturation and maintenance of a postsynaptic apparatus
Sanes, J. R., & Lichtman, J. W. (2001) · Nature Reviews Neuroscience · doi:10.1038/35097557 · Cited by 1,025
Gilhus, N. E., Tzartos, S., Evoli, A., Palace, J., Burns, T. M., & Verschuuren, J. J. G. M. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0079-y · Cited by 953
Self-citationAn adaptive coding model of neural function in prefrontal cortex
Duncan, J. (2001) · Nature Reviews Neuroscience · doi:10.1038/35097575 · Cited by 874
A systematic review of population based epidemiological studies in Myasthenia Gravis
Carr, A. S., Cardwell, C. R., McCarron, P. O., & McConville, J. (2010) · BMC Neurology · doi:10.1186/1471-2377-10-46 · Cited by 756
An adaptive coding model of neural function in prefrontal cortex
Duncan, J. (2001) · UCL Discovery (University College London) · Cited by 738
Bang, M.-L., Centner, T., Fornoff, F., Geach, A. J., Gotthardt, M., McNabb, M., Witt, C. C., Labeit, D., Gregorio, C. C., Granzier, H., et al. (2001) · Circulation Research · doi:10.1161/hh2301.100981 · Cited by 712
Lrp4 is a receptor for Agrin and forms a complex with MuSK
Kim, N., Stiegler, A. L., Cameron, T. O., Hallock, P. T., Gomez, A. M., Huang, J. H., Hubbard, S. R., Dustin, M. L., & Burden, S. J. (2008) · Cell · doi:10.1016/j.cell.2008.10.002 · Cited by 676
Gautam, M., Noakes, P. G., Mudd, J., Nichol, M., Chu, G. C., Sanes, J. R., & Merlie, J. P. (1995) · Nature · doi:10.1038/377232a0 · Cited by 545
Autoantibodies to low‐density lipoprotein receptor–related protein 4 in myasthenia gravis
Higuchi, O., Hamuro, J., Motomura, M., & Yamanashi, Y. (2011) · Annals of Neurology · doi:10.1002/ana.22312 · Cited by 535
IgG1 antibodies to acetylcholine receptors in ‘seronegative’ myasthenia gravis†
Leite, M. I., Jacob, S., Viegas, S., Cossins, J., Clover, L., Morgan, B. P., Beeson, D., Willcox, N., & Vincent, A. (2008) · Brain · doi:10.1093/brain/awn092 · Cited by 527
Tzartos, S. J., & Lindstrom, J. M. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.2.755 · Cited by 450
Self-citationMyasthenic Antibodies Cross-Link Acetylcholine Receptors to Accelerate Degradation
Drachman, D. B., Angus, C. W., Adams, R. N., Michelson, J. D., & Hoffman, G. J. (1978) · New England Journal of Medicine · doi:10.1056/nejm197805182982004 · Cited by 437
Clinical aspects of MuSK antibody positive seronegative MG
Sanders, D. B., El-Salem, K., Massey, J. M., McConville, J., & Vincent, A. (2003) · Neurology · doi:10.1212/01.wnl.0000065882.63904.53 · Cited by 407
Myasthenia gravis: A comprehensive review of immune dysregulation and etiological mechanisms
Berrih-Aknin, S., & Le Panse, R. (2014) · Journal of Autoimmunity · doi:10.1016/j.jaut.2013.12.011 · Cited by 383
ACUTE ANTERIOR UVEITIS AND HL-A 27
Brewerton, D. A., Caffrey, M., Nicholls, A., Walters, D., & James, D. C. O. (1974) · The Lancet · doi:10.1016/s0140-6736(74)92431-3 · Cited by 366
Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis
Pevzner, A., Schoser, B., Peters, K., Cosma, N.-C., Karakatsani, A., Schalke, B., Melms, A., & Kröger, S. (2012) · Journal of Neurology · doi:10.1007/s00415-011-6194-7 · Cited by 342
Tzartos, J. S. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.2393 · Cited by 342
Muscle and neuronal nicotinic acetylcholine receptors: Structure, function and pathogenicity
Kalamida, D., Poulas, K., Avramopoulou, V., Fostieri, E., Lagoumintzis, G., Lazaridis, K., Sideri, A., Zouridakis, M., & Tzartos, S. J. (2007) · The FEBS Journal · doi:10.1111/j.1742-4658.2007.05935.x · Cited by 333
Self-citationZisimopoulou, P., Evangelakou, P., Tzartos, J., Lazaridis, K., Zouvelou, V., Mantegazza, R., Antozzi, C., Andreetta, F., Evoli, A., Deymeer, F., et al. (2014) · Journal of Autoimmunity · doi:10.1016/j.jaut.2013.12.004 · Cited by 329
Self-citationA systematic review of diagnostic studies in myasthenia gravis
Benatar, M. (2006) · Neuromuscular Disorders · doi:10.1016/j.nmd.2006.05.006 · Cited by 301
MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4
Huijbers, M. G., Zhang, W., Klooster, R., Niks, E. H., Friese, M. B., Straasheijm, K. R., Thijssen, P. E., Vrolijk, H., Plomp, J. J., Vogels, P., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1313944110 · Cited by 297
Assembly of the postsynaptic membrane at the neuromuscular junction: paradigm lost
Kummer, T. T., Misgeld, T., & Sanes, J. R. (2006) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2005.12.003 · Cited by 291
HOWARD, F. M., LENNON, V. A., FINLEY, J., MATSUMOTO, J., & ELVEBACK, L. R. (1987) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1987.tb51321.x · Cited by 236
Antibodies against low-density lipoprotein receptor–related protein 4 induce myasthenia gravis
Shen, C., Lu, Y., Zhang, B., Figueiredo, D., Bean, J., Jung, J., Wu, H., Barik, A., Yin, D.-M., Xiong, W.-C., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66039 · Cited by 215
Autoimmune Targets of Heart and Skeletal Muscles in Myasthenia Gravis
Suzuki, S. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.229 · Cited by 188
Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis
Iorio, R., Damato, V., Alboini, P. E., & Evoli, A. (2015) · Journal of Neurology · doi:10.1007/s00415-014-7532-3 · Cited by 188
Koneczny, I., Cossins, J., Waters, P., Beeson, D., & Vincent, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080695 · Cited by 184
Patients with myasthenia gravis and thymoma have in their sera IgG autoantibodies against titin
AARLI, J. A., STEFANSSON, K., MARTON, L. S. G., & WOLLMANN, R. L. (2008) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.1990.tb05440.x · Cited by 184
Autoantibodies to Agrin in Myasthenia Gravis Patients
Zhang, B., Shen, C., Bealmear, B., Ragheb, S., Xiong, W.-C., Lewis, R. A., Lisak, R. P., & Mei, L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0091816 · Cited by 177
Striational Antibodies in Myasthenia Gravis
Romi, F. R., SKEIE, G. O., Gilhus, N. E., & Aarli, J. A. (2005) · Archives of Neurology · doi:10.1001/archneur.62.3.442 · Cited by 175
Anti-agrin autoantibodies in myasthenia gravis
Gasperi, C., Melms, A., Schoser, B., Zhang, Y., Meltoranta, J., Risson, V., Schaeffer, L., Schalke, B., & Kröger, S. (2014) · Neurology · doi:10.1212/wnl.0000000000000478 · Cited by 175
Riemersma, S., Vincent, A., Beeson, D., Newland, C., Hawke, S., Vernet-der Garabedian, B., Eymard, B., & Newsom-Davis, J. (1996) · Journal of Clinical Investigation · doi:10.1172/jci119048 · Cited by 161
MuSK is required for anchoring acetylcholinesterase at the neuromuscular junction
Cartaud, A., Strochlic, L., Guerra, M., Blanchard, B., Lambergeon, M., Krejci, É., Cartaud, J., & Legay, C. (2004) · The Journal of Cell Biology · doi:10.1083/jcb.200307164 · Cited by 159
Response to Therapy in Myasthenia Gravis with Anti‐MuSK Antibodies
Evoli, A., Bianchi, M. R., Riso, R., Minicuci, G. M., Batocchi, A. P., Servidei, S., Scuderi, F., & Bartoccioni, E. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1405.012 · Cited by 158
Arthrogryposis multiplex congenita with maternal autoantibodies specific for a fetal antigen
Vincent, A. C., Newland, C., Beeson, D., Riemersma, S. A., Newsom–Davis, J., Brueton, L., & Huson, S. (1995) · The Lancet · doi:10.1016/s0140-6736(95)92652-6 · Cited by 157
Antibody effector mechanisms in myasthenia gravis—Pathogenesis at the neuromuscular junction
Gomez, A. M., Broeck, J. V. D., Vrolix, K., Janssen, S. P. M., Lemmens, M. A. M., van der Esch, E., Duimel, H., Frederik, P. M., Molenaar, P. C., Martínez‐Martínez, P., et al. (2010) · Autoimmunity · doi:10.3109/08916930903555943 · Cited by 156
Studies on Purified Eel Acetylcholine Receptor and Anti-Acetylcholine Receptor Antibody
Patrick, J., Lindstrom, J. M., Culp, B., & Mcmillan, J. (1973) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.70.12.3334 · Cited by 152
Treatment-Refractory Myasthenia Gravis
Silvestri, N. J., & Wolfe, G. I. (2014) · Journal of Clinical Neuromuscular Disease · doi:10.1097/cnd.0000000000000034 · Cited by 151
Koneczny, I., Stevens, J., Rosa, A. D., Huda, S., Huijbers, M. G. M., Saxena, A., Maestri, M., Lazaridis, K., Zisimopoulou, P., Tzartos, S. J., et al. (2016) · Journal of Autoimmunity · doi:10.1016/j.jaut.2016.11.005 · Cited by 147
Self-citationMyasthenia Gravis in the Elderly
Aarli, J. A. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1405.040 · Cited by 142
Anti-MuSK autoantibodies block binding of collagen Q to MuSK
Kawakami, Y., Ito, M., Hirayama, M., Sahashi, K., Ohkawara, B., Masuda, A., Nishida, H., Mabuchi, N., Engel, A. G., & Ohno, K. (2011) · Neurology · doi:10.1212/wnl.0b013e318237f660 · Cited by 136
Ryanodine receptor autoantibodies in myasthenia gravis patients with a thymoma
Mygland, Å., Tysnes, O., Aarli, J. A., Gilhus, N. E., Matre, R., & Volpe, P. (1992) · Annals of Neurology · doi:10.1002/ana.410320419 · Cited by 132
LRP 4 antibodies in serum and CSF from amyotrophic lateral sclerosis patients
Tzartos, J. S., Zisimopoulou, P., Rentzos, M., Karandreas, N., Zouvelou, V., Evangelakou, P., Tsonis, A., Thomaides, T., Lauria, G., Andreetta, F., et al. (2013) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.26 · Cited by 117
Self-citationWilliams, C. L., & Lennon, V. A. (1986) · The Journal of Experimental Medicine · doi:10.1084/jem.164.4.1043 · Cited by 110
The search for new antigenic targets in myasthenia gravis
Cossins, J., Belaya, K., Zoltowska, K. M., Koneczny, I., Maxwell, S., Jacobson, L. W., Leite, M. I., Waters, P. J., Vincent, A. C., & Beeson, D. (2012) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2012.06833.x · Cited by 106
Ma, C.-G., Zhang, G.-X., Xiao, B.-G., Link, J., Olsson, T. P., & Link, H. (1995) · Journal of Neuroimmunology · doi:10.1016/0165-5728(94)00187-s · Cited by 96
Myasthenia gravis patients with ryanodine receptor antibodies have distinctive clinical features
Romi, F. R., Aarli, J. A., & Gilhus, N. E. (2007) · European Journal of Neurology · doi:10.1111/j.1468-1331.2007.01785.x · Cited by 75
Cordts, I., Bodart, N., Hartmann, K., Karagiorgou, K., Tzartos, J. S., Mei, L., Reimann, J., Damme, P. V., Rivner, M. H., Vigneron, A., et al. (2017) · Journal of Neurology · doi:10.1007/s00415-017-8514-z · Cited by 67
Self-citationRivner, M. H., Liu, S. M., Quarles, B. M., Fleenor, B., Shen, C., Pan, J., & Mei, L. (2016) · Muscle & Nerve · doi:10.1002/mus.25438 · Cited by 57
Vrolix, K., Fraussen, J., Losen, M. H., Stevens, J., Lazaridis, K., Molenaar, P. C., Somers, V. A., Bracho, M. A., Panse, R. L., Stinissen, P., et al. (2014) · Journal of Autoimmunity · doi:10.1016/j.jaut.2013.12.008 · Cited by 56
Self-citationKufukihara, K., Watanabe, Y., Inagaki, T., Takamatsu, K., Nakane, S., Nakahara, J., Ando, Y., & Suzuki, S. (2019) · Scientific Reports · doi:10.1038/s41598-019-41730-z · Cited by 56
Kordas, G., Lagoumintzis, G., Sideris, S., Poulas, K. A., & Tzartos, S. J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0108327 · Cited by 54
Self-citationAntibodies identified by cell‐based assays in myasthenia gravis and associated diseases
Vincent, A. C., Waters, P. J., Leite, M. I., Jacobson, L. W., Koneczny, I., Cossins, J., & Beeson, D. (2012) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2012.06789.x · Cited by 49
Induction of Anti-agrin Antibodies Causes Myasthenia Gravis in Mice
Yan, M., Liu, Z., Fei, E., Chen, W., Lai, X., Luo, B., Chen, P., Jing, H., Pan, J., Rivner, M. H., et al. (2018) · Neuroscience · doi:10.1016/j.neuroscience.2018.01.015 · Cited by 48
Serum antibodies to collagen XIII: a further good marker of active Graves’ ophthalmopathy
Bellis, A. D., Sansone, D., Coronella, C., Conte, M. L., Iorio, S., Perrino, S., Battaglia, M., Bellastella, G., Wall, J. R., Bellastella, A., et al. (2004) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.02167.x · Cited by 46
Eymard, B., Garabedian, B. V.-D., Berrih‐Aknin, S., et al. (1991) · Journal of Autoimmunity · doi:10.1016/0896-8411(91)90017-7 · Cited by 41
Anti‐LRP4 autoantibodies in Chinese patients with myasthenia gravis
Li, Y., Zhang, Y., Cai, G., He, D., Dai, Q., Zhu, X., & Chu, L. (2017) · Muscle & Nerve · doi:10.1002/mus.25591 · Cited by 40
Mappouras, D. G., Philippou, G., Haralambous, S., Tzartos, S. J., Balafas, A., Souvatzoglou, A., & Lymberi, P. (1995) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.1995.tb03674.x · Cited by 39
Self-citationMolecular and Antigenic Structure of Nicotinic Acetylcholine Receptors
Lindstrom, J. M., Peng, X.-D., Kuryatov, A., Lee, E. B., Anand, R., Gerzanich, V., WANG, F., Wells, G. B., & NELSON, M. (1998) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1998.tb10910.x · Cited by 38
Li, M., Han, J., Zhang, Y., Lv, J., Zhang, J., Zhao, X., Ren, L., Fang, H., Yang, J. C., Zhang, Y., et al. (2019) · European Journal of Neurology · doi:10.1111/ene.13979 · Cited by 37
AChR-specific immunosuppressive therapy of myasthenia gravis
Luo, J., & Lindstrom, J. M. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.07.011 · Cited by 34
MuSK‐positive myasthenia gravis is rare in the Polish population
Kostera‐Pruszczyk, A., Kamińska, A., Dutkiewicz, M., et al. (2008) · European Journal of Neurology · doi:10.1111/j.1468-1331.2008.02176.x · Cited by 34
Myasthenia Gravis and the Tops and Bottoms of AChRs
Lindstrom, J. M., Luo, J., & Kuryatov, A. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1405.007 · Cited by 32
Kostelidou, K., Τράκας, Ν., & Tzartos, S. J. (2007) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2007.07.018 · Cited by 32
Self-citationCurrent pharmacotherapeutic options for myasthenia gravis
Barnett, C., Tabasinejad, R., & Bril, V. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1682548 · Cited by 27
Antigenic Structure of the Human Muscle Nicotinic Acetylcholine Receptor Main Immunogenic Region
Luo, J., & Lindstrom, J. M. (2009) · Journal of Molecular Neuroscience · doi:10.1007/s12031-009-9271-y · Cited by 23
Antigen-Specific Immunotherapeutic Vaccine for Experimental Autoimmune Myasthenia Gravis
Luo, J., & Lindstrom, J. M. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1401392 · Cited by 22
Ching, K. H., Burbelo, P. D., Kimball, R. M., Clawson, L., Corse, A. M., & Iadarola, M. J. (2010) · Neuromuscular Disorders · doi:10.1016/j.nmd.2010.12.003 · Cited by 21
Specific immunotherapy of experimental myasthenia gravis by a novel mechanism
Luo, J., Kuryatov, A., & Lindstrom, J. M. (2009) · Annals of Neurology · doi:10.1002/ana.21901 · Cited by 21
Lazaridis, K., Evaggelakou, P., Bentenidi, E., Sideri, A., Grapsa, E., & Tzartos, S. J. (2014) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2014.12.001 · Cited by 19
Self-citationYi, H., Chae, C.-S., So, J., Tzartos, S. J., Souroujon, M. C., Fuchs, S., & Im, S. (2008) · Molecular Immunology · doi:10.1016/j.molimm.2008.08.264 · Cited by 18
Self-citationExpression of human AChR extracellular domain mutants with improved characteristics
Lazaridis, K., Zisimopoulou, P., Giastas, P., Bitzopoulou, K., Evangelakou, P., Sideri, A., & Tzartos, S. J. (2013) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2013.11.003 · Cited by 16
Self-citationLazaridis, K., Dalianoudis, I., Baltatzidi, V., & Tzartos, S. J. (2017) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2017.09.001 · Cited by 16
Self-citationThe Road Not Taken: Antigen-Specific Therapy and Neuroinflammatory Disease
Steinman, L. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.3553 · Cited by 14
The Prevalence of Anti-acetylcholinesterase Antibodies in Autoimmune Disease
Geen, J., Howells, R. C., Ludgate, M. E., Hullin, D. A., & Hogg, S. I. (2004) · Autoimmunity · doi:10.1080/08916930400021360 · Cited by 13
Cited by
Pathogenesis of autoimmune disease
Pisetsky, D. S. (2023) · Nature Reviews Nephrology · doi:10.1038/s41581-023-00720-1 · Cited by 649
Targeting the Neonatal Fc Receptor in Autoimmune Diseases: Pipeline and Progress
Gjølberg, T. T., Mester, S., Calamera, G., Telstad, J. S., Sandlie, I., & Andersen, J. T. (2025) · BioDrugs · doi:10.1007/s40259-025-00708-2 · Cited by 20
Metadata
- Authors
- Lazaridis, K., & Tzartos, S. J.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2020-02-14
- Volume
- 11
- Pages
- 212-212
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W3006331137
- Cited by
- 287
- References
- 77
- FWCI
- 11.31
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.